|
|
NEWS
RECALLS
COMPLAINT FORM
SCAM ALERTS
RESOURCES
Small Claims Guide Class Actions Lemon Laws FAQ Newsletters |
| Automotive Education Employment Electronics Family Finance Health Homeowners Pets Shopping Travel |
|
|
![]() |
FDA Orders "Black Box" Warning for Asthma Drugs |
|||||
|
July 14, 2005
Made by GlaxoSmithKline, the medications contain salmeterol, a bronchodilator known as a beta2-agonist. It works by relaxing the bronchial muscles, thereby improving air flow for many of the 15 million asthma sufferers in the U.S. Regulators became alarmed when Glaxo reported that it had to stop tests of the drug when about 50 out of 26,000 patients being studied suffered more severe asthma attacks. A few died. After a review by its panel of experts, the FDA voted 12-0 to keep the drugs on the market while adding a "black box" warning, the most extreme warning that can be put on drugs. The tests were launched in 1996 at the behest of the FDA to address specific questions about Serevent and Advair. In 2003, the trials were stopped after 50 people experienced serious, life-threatening episodes or died, compared with 36 episodes in patients who had been given a placebo. One statistic that initially raised concerns was that African-Americans in the study appeared to have a higher rate of death. Twenty black people who had receive the drug died, compared with five who were taking the placebo. But doctors involved in the study and other researchers agreed that the statistic was misleading and did not indicate that blacks were at higher risk of dying from taking the drugs. FDA panelists stressed that the higher death rate in the test was a fluke and that it would be irresponsible to mislead blacks into turning from medication that could prolong their lives. Asthma is a dangerous disease, especially when it is untreated or under-treated. No one now taking prescribed medications should stop taking them without consulting their physician. It can be dangerous to suddenly stop taking prescribed medications. Sales of Servent and Advair, marketed as Seretide in Europe, topped $4 billion last year. Novartis' asthma remedy, Foradil, which was also reviewed, brought in only $320 million. Report Your Experience
|
|
||||
Advertisement
|
|
Custom Search
|
||||
|
AUTOMOTIVE Dealers Manufacturers Service Extended Warranties Lemon Laws Recalls Tires Transporters FAMILY Aging Children, Parenting Recalls Dating Education Entertainment Pets Weddings |
FINANCE Annuities Banks Credit Cards Debt Collection Debt Counseling Insurance Investing Loans Mortgages Payday Loans Student Loans Tax Prep HEALTH Doctors Drugs, Pharmacies Health Clubs Hearing Care Hospitals Nursing Homes Nutrition, Diets Vision Care Weight Loss |
HOMEOWNERS & RENTERS Appliances Cookware Furniture Home Improvements Lawn & Garden Movers Pools & Spas Realtors, Rental Agents Recalls Utilities ELECTRONICS Cable TV/DBS Cameras Cell Phones Computers Home Electronics Internet Access Local Phone Service Long Distance VoIP |
SHOPPING In-Home Online Retail Stores Sporting Goods Supermarkets Telemarketers TRAVEL Airlines Bus Lines Car Rental Cruises Hotels Travel Agents Trains RESOURCES Class Actions Complaint Form Small Claims Guide Lemon Laws |
CONSUMER NEWS Latest News Automotive Telecom Financial Health Homeowners Scams Seniors Travel More ... RECALLS Automotive Children's Products Drugs Food Household Products Sporting Goods ABOUT US FAQ Privacy Policy Advertise With Us Newsroom Syndication Terms of Use |
Terms of Use Your use of this site constitutes acceptance of the Terms of Use
Copyright © 2003-2009 ConsumerAffairs.com Inc. All Rights Reserved. The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission. |
|